Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 18/20 | 0.55 |
| ▸ | CDK8 | P49336 | 18/20 | 0.55 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831253 | 1.00 | CCNC (0.55) | CCNCCDK8CDK19MCHR1CHRM1 | |
| SCHEMBL1006234 | 0.92 | CCNC (0.64) | CCNCCDK8CDK19 | |
| SCHEMBL1006232 | 0.92 | CCNC (0.64) | CCNCCDK8CDK19 | |
| SCHEMBL4877142 | 0.91 | CCNC (0.51) | CCNCCDK8CDK19MCHR1CHRM1 | |
| SCHEMBL4877138 | 0.91 | CCNC (0.51) | CCNCCDK8CDK19MCHR1CHRM1 | |
| SCHEMBL4877149 | 0.91 | CCNC (0.51) | CCNCCDK8CDK19MCHR1CHRM1 | |
| SCHEMBL4826330 | 0.87 | CCNC (0.49) | CCNCCDK8CDK19 | |
| SCHEMBL4826317 | 0.87 | CCNC (0.49) | CCNCCDK8CDK19 | |
| SCHEMBL4825984 | 0.86 | CCNC (0.45) | CCNCCDK8CDK19MCHR1CHRM1 | |
| SCHEMBL4825979 | 0.86 | CCNC (0.45) | CCNCCDK8CDK19MCHR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | CCNC 2548/4885CDK8 2963/4885CDK19 2585/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | CCNC 2548/4885CDK8 2963/4885CDK19 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.